(Q34975667)

5 August 2017

1 reference

title

Imatinib mesylate, the first molecularly targeted gene suppressor (English)

1 reference

5 August 2017

1 reference

Vanita K Pindolia

1

1 reference

5 August 2017

Barbara J Zarowitz

series ordinal

2

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 October 2002

1 reference

5 August 2017

1 reference

5 August 2017

volume

22

1 reference

5 August 2017

issue

10

1 reference

5 August 2017

page(s)

1249-1265

1 reference

5 August 2017

cites work

Chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.15.1249.33482

Gastrointestinal stromal tumors: recent advances in understanding of their biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.15.1249.33482

Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.15.1249.33482

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.15.1249.33482

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.15.1249.33482

Chronic myeloid leukaemia. STI 571 magnifies the therapeutic dilemma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.15.1249.33482

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.15.1249.33482

Platelet-derived growth factor receptors: a therapeutic target in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.15.1249.33482

STI571: targeting BCR-ABL as therapy for CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.15.1249.33482

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.15.1249.33482

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.15.1249.33482

STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.15.1249.33482

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.15.1249.33482

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.15.1249.33482

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.15.1249.33482

Roots of clinical resistance to STI-571 cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.15.1249.33482

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.15.1249.33482

Cutaneous reactions to STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.15.1249.33482

Chronic myeloid leukemia: current treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.15.1249.33482

Non-myeloablative stem cell transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.15.1249.33482

Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.15.1249.33482

10.1592/PHCO.22.15.1249.33482

21 January 2018

Identifiers

DOI

1 reference

release_xazaqxsfgnfrta7gjwhxpmanyy

5 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/xazaqxsfgnfrta7gjwhxpmanyy

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference